Biopharma’s Boom and Bust

Several stocks have surged since going public over the past two weeks, but the jury is out as to whether they can sustain these gains.


Illustration by II

Kyverna Therapeutics is the latest biopharma company to see its stock jump following an initial public offering.

The clinical-stage company focuses on developing cell therapies for patients suffering from autoimmune diseases. It is up about 37 percent since it began trading on Thursday.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.